# RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

> **NCT03412409** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Acute Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03412409
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412409, "RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03412409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*